Aptose Biosciences closes public offering of US$21.3M in common shares

On June 3, 2019, Aptose Biosciences ("Aptose") completed its public offering of 10,000,000 common shares at US$1.85 per shares, for aggregate gross proceeds of US$21.3 million. The public offering included the exercise in full by the underwriters of their option to purchase 1,500,000 additional common shares. RBC Capital Markets and Canaccord Genuity acted as joint book-running managers for the offering. H.C. Wainwright & Co. and JonesTrading Institutional services LLC acted as co-managers.

Aptose intends to use the proceeds from the offering to expand its clinical trial programs, and for working capital and general purposes.

Aptose, headquartered in Toronto, Ontario, is a biopharmaceutical company. It focuses on the discovery, research and development of anti-cancer therapies.

McCarthy Tétrault LLP represented Aptose, the issuer, with a team led by Charles-Antoine Soulière, that included Felipe Diaz Villegas, Vincent Laurin and Annie Poirier-Simard.